The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 30, 2023

Filed:

Mar. 24, 2017
Applicants:

Stcube, Inc., Seoul, KR;

Board of Regents, the University of Texas System, Austin, TX (US);

Inventors:

Stephen S. Yoo, Centreville, VA (US);

Ezra M. Chung, North Potomac, MD (US);

Yong-Soo Kim, Rockville, MD (US);

Kyu Lee Han, Gaithersburg, MD (US);

Andrew H. Park, Gaithersburg, MD (US);

Mien-Chie Hung, Houston, TX (US);

Chia-Wei Li, Houston, TX (US);

Seung-Oe Lim, Houston, TX (US);

Assignees:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61K 39/00 (2006.01); A61K 39/44 (2006.01); C07K 16/00 (2006.01); C07K 16/46 (2006.01); A61K 47/68 (2017.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); A61P 35/00 (2006.01);
U.S. Cl.
CPC ...
A61K 47/6811 (2017.08); A61K 47/6849 (2017.08); A61K 47/6851 (2017.08); A61K 47/6879 (2017.08); A61P 35/00 (2018.01); C07K 16/2827 (2013.01); C07K 16/3015 (2013.01); C07K 16/3023 (2013.01); C07K 2317/30 (2013.01); C07K 2317/34 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2317/77 (2013.01);
Abstract

Antibodies that bind specifically to glycosylated PD-L1 relative to unglycosylated PD-L1, block binding of PD-L1 to PD-1 and promote internalization and degradation of PD-L1 are provided. Antibodies that recognize specific epitopes on glycosylated PD-L1 protein and that exhibit the dual functions of both blocking the binding of PD-L1 to PD-1 and also facilitating the internalization of PD-L1 on cells are provided. In some aspects, PD-L1 polypeptides comprising glycosylated amino acid residues at amino and carboxy terminal positions of the PD-L1 extracellular domain are also provided. Methods for using such antibodies for the treatment of cancer, particularly PD-L1 positive cancer, are also provided.


Find Patent Forward Citations

Loading…